PDS Biotechnology

Historical price data

PDS Biotech is focused on transforming how the immune system targets and fights disease through its Versamune® T-cell activating platform and its combination with the tumor-targeted IL-12 immunocytokine PDS01ADC. The company has demonstrated promising clinical results in HPV-positive cancers, including a median overall survival of 39.3 months in a Phase 2 head and neck cancer trial. With a growing pipeline in oncology and infectious disease vaccines, PDS Biotech aims to create a new generation of targeted immunotherapies.

Versamune® is a cationic lipid-based nanoparticle T-cell activating platform that generates potent tumor-infiltrating T cells, while PDS01ADC is a tumor-targeted IL-12 immunocytokine that modifies the tumor microenvironment to enhance T-cell activity.

2 drugs in pipeline, 1 in Phase 3

PDS Biotech competes with large pharmaceutical companies like Merck and Bristol-Myers Squibb in HPV-associated cancers, but differentiates through its T-cell generating mechanism versus checkpoint inhibitors' approach of releasing T-cell brakes. The company's combination platform (Versamune® + PDS01ADC) offers a unique dual approach of generating T cells while modifying the tumor microenvironment.